Why I think the future of lipedema is subgrouping
I think the future of lipedema is subgrouping..
Most lipedema descriptions still rely on “types” and “stages.” They can help describe how the tissue looks, but they often miss what actually determines daily burden: who has the most pain, the most swelling, the most bruising, the most stiffness, or the most additional health issues. The German S2k guideline is also clear on an important point: the visible, morphological staging should not be used as a measure of disease severity, and we still don’t have a validated system for staging lipedema based on symptoms. That gap matters, because symptoms are what decide quality of life.
A more useful way forward is to describe lipedema on two levels at the same time: an outer “phenotype” level (how it looks and feels), and an inner “endotype” level (what seems to drive it biologically).
As a starting point, I still look at distribution in the limbs, but in a descriptive way rather than rigid “type 1–5.” In the S2k description, lipedema is a painful, symmetrical, disproportionate fat distribution in the extremities (typically legs and/or arms), while hands and feet are not affected. In real life, this creates practical subgroups that often matter more than a label. Some are leg-dominant (no arms). Some have legs plus arms. And many have a clear “segment dominance,” meaning the main load sits more around thighs/knees versus closer to calves/ankles. This often affects walking mechanics, skin friction, irritation, and which compression solutions are realistic and effective.
The next step is to think in “drivers.” These are not separate diagnoses, and they can overlap, but usually one pattern dominates. The point is to match the management strategy to what is actually causing the biggest burden.
For some, the dominant driver is fluid and upright strain. They describe heaviness, clear day-to-day variation, and a strong “water component.” The S2k guideline discusses findings pointing toward changes in microcirculation and permeability, differences in measured tissue fluid (for example via bioimpedance), and even increased tissue sodium in the lower limbs measured with sodium MRI in lipedema patients. In practice, this is often the group that feels the clearest symptom relief from well-fitted compression, reducing long periods of standing still, and the right dose of “muscle pump” activity—even if the fat volume doesn’t change quickly.
For others, the dominant driver looks more vascular: easy bruising, fragile capillaries, and a strong bruising tendency that becomes a core symptom. The guideline points to microangiopathy as a plausible explanation, and also describes that lipedema tissue can be highly vascular with enlarged blood vessels. In this subgroup, it becomes especially important to assess for co-existing venous insufficiency, and to think in terms of supporting the “barrier” in the vascular system, not only focusing on volume.
A third pattern is immune and inflammation-driven pain. Here, pain and tenderness can be out of proportion to the visible volume, and the biology seems less like pure “mechanics” and more like the tissue’s immune environment. The S2k summary includes studies showing increased immune cell infiltration—especially macrophages (CD68+)—and data suggesting a shift toward a more M2-like (immune-modulating) macrophage state in lipedema fat. For women in this subgroup, strategies that influence systemic inflammation, sleep quality, pain sensitisation, and graded activity can be just as important as anything aimed at size or volume.
A fourth pattern is fibrosis and stiffness. The tissue feels firmer or nodular, the layers don’t glide as well, and function becomes a large part of the burden—friction, skin folds, mobility, and how the body moves. The guideline describes that lipedema-affected fat tissue can be fibrotic. This is often the group where conservative measures can reduce symptoms, but where true, long-term reduction of disease tissue is harder without surgical strategies if lasting volume change is the goal.
A fifth important subgroup is lymphatic overlap, sometimes described as lipolymphedema. This matters because lymphedema can develop secondarily and changes both the examination and the treatment goals. The US Standard of Care describes that women at any stage can have lymphedema, but it becomes more likely in more advanced stages. The S2k guideline also stresses that obesity can cause obesity-associated lymphedema, which can be confused with—or layered on top of—lipedema. In this subgroup, fluid management and true lymphatic competence become central: compression, skin care, infection prevention, and appropriate lymphatic therapy (including CDT where relevant).
A sixth pattern is metabolic comorbidity as a strong amplifier. This is where trunk weight gain, insulin resistance, or broader metabolic strain clearly worsens symptoms, function, and progression risk—without reducing lipedema to “just obesity.” The S2k guideline is explicit that lipedema is not caused by obesity and does not itself cause obesity, but obesity often co-exists and increases total burden. In this subgroup, the practical question is treatment strategy: what is likely lipedema tissue, and what is modifiable metabolic risk that can give a meaningful symptom payoff when addressed.
On top of phenotype and endotype, I would always add a hormone-sensitivity marker—not as a separate diagnosis, but as a way to stratify the story. Did onset or progression happen around puberty, pregnancy, or menopause? Do symptoms shift with the cycle or hormone treatment? Clinical overviews repeatedly note that hormonal changes seem involved, even if the exact mechanism is not fully clarified. Looking forward, newer proposals for thinking about “stage” are also beginning to weigh factors like pain, water, fat, and skeletal muscle rather than only skin texture or nodularity—because that better reflects biological drivers and function.
The goal is simple: to move from “What stage am I?” to “What profile do I have right now?” That shift can make lipedema management more targeted, more realistic, and more personal.
Then there's me. I am all the subgroups you mention. I suffer from them all. I often wonder if I'm suffering the same disease as everyone else because the the pain is more, the fibrosis is more, the tightness & restriction is immobilizing, the swelling is more, yes I have veinous issues yet not the bruising, the insulin sensitivity almost seems unrealistic, joint issues are extreme yet I'm not overweight anymore tho I have been in the past, and I have none of the comorbidity diseases everyone else has besides some hypermobility but probably not bad enough to be hEDS, and yet I am only stage 2 and a year ago couldn't barely walk, stand, or use stairs. My day always ended with an hour soak in a hot tub of Epsom Salt just to be able to get up and do it again. Conservative measures have helped with diagnosis but my suffering seems so much worse than others of similar age & stage. I know why the standard of care in US was written the way it was and I fully support prevention but sometimes its frustrating because I feel like I suffer so much more than I feel other women who are stage 2 do yet we are in the same category.
this articulates something i’ve been trying to document — the fundamental disconnect between how lipoedema actually presents and how medical systems attempt to categorise it.
what strikes me most is the recognition that lipoedema might not be a singular disease entity at all. this matches what i’ve observed: the diagnostic criteria feel simultaneously too broad (catching people with very different experiences) and too narrow (missing presentations that don’t fit the textbook description).
your point about moving away from the lymphatic system hypothesis toward understanding this as potentially vascular or metabolic feels crucial.
it explains why so many treatments fail — they’re addressing the wrong underlying mechanism. my body has been telling me this for years through its refusal to respond to conventional approaches.
this is exactly why patient documentation matters. we’re living inside these diagnostic failures, experiencing directly how current frameworks don’t work. the medical establishment needs to stop forcing our experiences into inadequate categories and start building understanding from what we’re actually reporting.